TLSI earnings analysis
What we found in TLSI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
TriSalus Life Sciences reported Q1 2026 results, with revenue of $8.9 million, a decrease of 2.9% year-over-year. The company achieved an EPS of $0.03, significantly beating expectations of -$0.16. Despite a slight drop in revenue, gross margins improved from 83.7% to 86.2%, signaling operational efficiencies. However, increased operating losses and ongoing reliance on external financing remain critical areas of concern.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue of $8.9M, but down 2.9% YoY
- Revenue decreased by $0.3 million from Q1 2025 due to commercial expansion.
- EPS of $0.03 beats estimates
- EPS exceeded estimates of -$0.16, showcasing unexpected profitability.
- Gross margin improved to 86.2%
- Gross margin increased from 83.7% in the prior year, indicating better cost management.
- Interest income rises to $164K
- Interest income increased compared to the previous year, reflecting a higher cash balance.
- Substantial financing activity of $42.4M
- Net cash provided by financing activities increased significantly due to a public offering.
- Reduction in cost of goods sold by 17.7%
- Cost of goods sold dropped to $1.23M, allowing for improved gross profit performance.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Operating losses increased to $8.4M
- Operating losses rose from $7.3 million in Q1 2025, raising concerns over sustainability.
- Reliance on external financing
- Continued need for additional capital raises from equity or debt financing to fund operations.
- Material weakness in financial controls persists
- Management identified ongoing issues in internal controls affecting financial reporting quality.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.03
- Gross margin
- 86.2%
What they said about what is next.
Anticipates revenue between $54M to $57M for the fiscal year 2026, reflecting ongoing expansion.
The filing reads better than the one before it.
What came before.
- 10-K · March 5, 2026
- TriSalus positions itself as an oncology-focused med-tech platform combining its FDA-cleared PEDD delivery devices (TriNav) with an investigational immunotherapeutic, nelitolimod, to address drug delivery limits in…
- 10-Q · August 12, 2025
- TriSalus reported Q2 revenue of $11.213M (up $3.849M or ~52% vs Q2 2024) with gross profit of $9.411M and a gross margin of ~83.9%. The company remains unprofitable (net loss attributable to common stockholders of…
- 10-Q · May 15, 2025
- TriSalus reported strong top-line growth for the quarter with revenue of $9,167,000 (up $2,710,000 or ~42% YoY) and gross profit of $7,672,000 (gross margin ~83.7%). Operating loss narrowed to $(7,329,000) from…
- 10-K · April 15, 2025
- TriSalus describes a platform strategy combining its FDA‑cleared PEDD delivery devices (TriNav family) with an investigational immunotherapeutic, nelitolimod, to improve intratumoral delivery and responses in liver and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TLSI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever